Compare · GPUS vs TMO
GPUS vs TMO
Side-by-side comparison of Hyperscale Data Inc. (GPUS) and Thermo Fisher Scientific Inc (TMO): market cap, price performance, sector, and recent activity on the wire.
Summary
- GPUS operates in Technology, while TMO operates in Industrials - the two are in different parts of the market.
- TMO is the larger of the two at $257.53B, about 5103.1x GPUS ($50.5M).
- GPUS has been more active in the news (23 items in the past 4 weeks vs 7 for TMO).
- TMO has more recent analyst coverage (25 ratings vs 0 for GPUS).
- Company
- Hyperscale Data Inc.
- Thermo Fisher Scientific Inc
- Price
- -
- -
- Market cap
- $50.5M
- $257.53B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Industrial Machinery/Components
- Industrial Machinery/Components
- Exchange
- AMEX
- NYSE
- IPO
- 1997
- News (4w)
- 23
- 7
- Recent ratings
- 0
- 25
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. It has a strategic alliance with the University of California, San Francisco. The company was incorporated in 1956 and is based in Waltham, Massachusetts.
Latest GPUS
- Hyperscale Data Announces Plan for its askROI Subsidiary to Go Public in the Second or Third Quarter of 2027
- Hyperscale Data Completes Tokenization of 5,000 Troy Ounces of Physical Silver; Tokens Are Listed on Ault Markets with Trading Anticipated to Commence Within Weeks
- Hyperscale Data Announces Preliminary Third Quarter 2026 Revenue of Approximately $40 Million, Up 64% Compared to Third Quarter 2025
- Hyperscale Data Announces Plans for up to $33.5 Million in Tokenized Series D Preferred Stock Offering
- SEC Form 424B5 filed by Hyperscale Data Inc.
- SEC Form 8-K filed by Hyperscale Data Inc.
- Hyperscale Data Announces a Two Hundred Million Dollar Reduction in the Amount of Sales that May Be Made under the Sales Agreement Providing for Its Current ATM Offering
- Hyperscale Data Announces Live Access to Decentralized Exchange on the Ault Blockchain through Ault Markets
- Hyperscale Data Held Approximately $56.4 Million of Bitcoin, Cash and Restricted Cash as of October 4, 2026
- Hyperscale Data Sets November 12 as Investor Day to Discuss Michigan AI Expansion and Strategic Alternatives Across Its Portfolio
Latest TMO
- SEC Form 4 filed by Director Weisler Dion J
- SEC Form 4 filed by Director Sperling Scott M
- SEC Form 4 filed by Director Lynch Karen S
- SEC Form 4 filed by Director Johnson Jennifer M
- SEC Form 4 filed by Director Keith R. Alexandra
- Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, October 21, 2026
- Thermo Fisher Scientific Launches Gibco™ CHO-K1 Catalog Panel Media and Feed to Accelerate Biologics Development
- Thermo Fisher upgraded by UBS with a new price target
- CLSA initiated coverage on Thermo Fisher with a new price target
- Executive Vice President Shafer Michael D covered exercise/tax liability with 790 shares, decreasing direct ownership by 4% to 20,204 units (SEC Form 4)